Assessing the requirements of prenatal UBE3A expression for rescue of behavioral phenotypes in a mouse model for Angelman syndrome.

The study was conducted in mice, and the timing of brain development differs significantly from humans, making it uncertain how these critical windows translate to human patients. Most behavioral tests used have limited direct clinical value and do not clearly map to specific human functional deficits. The study was underpowered to detect small effects in some tasks, such as the open field test. While paternal gene loss did not cause significant behavioral deficits, a small effect cannot be entirely ruled out.

Funding was provided by Associazione Angelman (IT), the Chinese Scholarship Council (CSC), and NWO-ZoN-MW. No specific conflicts of interest were declared by the authors.

Do not assume that prenatal gene therapy is required for human Angelman syndrome based on this mouse data. The study suggests that restoring expression just before birth was sufficient in mice, and that paternal loss during prenatal development had no measurable behavioral impact, implying that postnatal intervention might still be effective in this model.